Phase 3 N=10 Emotional Processing and Oxytocin Mechanisms in Premenstrual Dysphoric Disorder: A Pilot Study
Premenstrual Dysphoric Disorder
Primary: Change in Premenstrual Symptom Severity — 25.05; 27.36 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=645 Brief Motivational Interviewing to Reduce Child Body Mass Index
Childhood Obesity
Primary: Child BMI Percentile — 90.31; 88.1; 87.1 BMI Percentile
Phase 2 N=46 Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck
Squamous Cell Carcinoma of the Head and Neck
Primary: Objective Response Rate (ORR) — 0; 2 participants
Phase 3 N=665 Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma
Localized Resectable Neuroblastoma · Localized Unresectable Neuroblastoma · Recurrent Neuroblastoma
Primary: Event-free Survival Rate — 48.8; 61.8 percent probability — p=0.0082
Phase 4 N=20 Testosterone Gel Applied to Women With Pituitary Gland Problems
Panhypopituitarism
Primary: Fatigue Impact Scale — -22.9; 2.2 units on a scale — p=0.08
N/A N=19 Pilot Test of a Chinese Menu Plan for Type 2 Diabetes
Type 2 Diabetes
Primary: Change in Energy Intake (3-day Food Record) — -299 kcal
Phase 4 N=34 Open-label Study of Subcutaneous Secukinumab to Evaluate Efficacy and Safety in Patients With Plaque Psoriasis Who Had Inadequate Response to Cyclosporine A
Plaque Psoriasis
Primary: Percentage of Participants Who Achieved ≥ 75% Psoriasis Area and Severity Index (PASI 75) — 82.4 Percentage of participants
Phase 4 N=12 Use of Sildenafil (Viagra) to Alter Fatigue, Functional Status and Impaired Cerebral Blood Flow in Patients With CFS
Chronic Fatigue Syndrome
Primary: Change in Fatigue Impact Scale at 6 Weeks — -32.6; -1.5 units on a scale — p=< 0.05
Phase 2 N=28 Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Breast Cancer
Primary: Maximum-tolerated Dose (Phase I) — 1; 3 Participants
Phase 2 N=215 S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer
Breast Cancer
Primary: Number of Patients With Pathological Complete Response Rate — 35; 24 Participants — p=0.019
N/A N=47 Efficacy of Dx-pH Probe in Diagnosing Extra-esophageal Reflux Disease
GERD · Larynx Disease
Primary: Decrease in pH From Baseline to <4 — 1.1; 3.2; 3.8 distal esophagus total % time pH <4 — p=.05
Phase 2 N=3 Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Glioblastoma Multiforme
Primary: Number of Participants With Dose Limiting Toxicities to Determine Maximum Tolerated Dose (MTD) of Dasatinib in Combination With Bevacizumab (Phase I) — 0; 0; 0; 0…
Phase 2 N=55 Hypophosphatemia With Ferric Carboxymaltose Vs. Iron Dextran in Iron Deficiency Secondary to Heavy Uterine Bleeding
Iron Deficiency Anemia
Primary: Changes in Blood Markers — -.38; -.08 mg/dL
Phase 4 N=42 Study to Assess Impact of Dysport Injections Early After Stroke on Upper Limb Spasticity Progression
Stroke · Upper Limb Spasticity
Primary: Time Between the Initial Injection and the Appearance of Reinjection Criteria as Evaluated by the Modified Ashworth Scale (MAS) and Spasticity Symptoms — 156; 32 days…
N/A N=4,182 Text Reminders to Immunize in a Managed Care Organization
Human Papilloma Virus
Primary: Percentage of Participants Receiving HPV Vaccination (Dose 1) — 16; 13 percentage of eligible participants — p=<0.04